These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22487056)

  • 1. PEGylation of supercooled smectic cholesteryl myristate nanoparticles.
    Mengersen F; Bunjes H
    Eur J Pharm Biopharm; 2012 Jun; 81(2):409-17. PubMed ID: 22487056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of preparation conditions and heat treatment on the properties of supercooled smectic cholesteryl myristate nanoparticles.
    Kuntsche J; Bunjes H
    Eur J Pharm Biopharm; 2007 Nov; 67(3):612-20. PubMed ID: 17574399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of stabilizer systems on the properties and phase behavior of supercooled smectic nanoparticles.
    Kuntsche J; Koch MH; Steiniger F; Bunjes H
    J Colloid Interface Sci; 2010 Oct; 350(1):229-39. PubMed ID: 20619846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystallization behavior of supercooled smectic cholesteryl myristate nanoparticles containing phospholipids as stabilizers.
    Kuntsche J; Koch MH; Drechsler M; Bunjes H
    Colloids Surf B Biointerfaces; 2005 Jul; 44(1):25-35. PubMed ID: 15990283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical stability of phospholipid-stabilized supercooled smectic cholesteryl myristate nanoparticles.
    Mengersen F; Bunjes H
    Eur J Pharm Biopharm; 2012 Oct; 82(2):262-71. PubMed ID: 22750438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supercooled smectic nanoparticles: influence of the matrix composition and in vitro cytotoxicity.
    Kuntsche J; Koch MH; Fahr A; Bunjes H
    Eur J Pharm Sci; 2009 Oct; 38(3):238-48. PubMed ID: 19664705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supercooled smectic nanoparticles: a potential novel carrier system for poorly water soluble drugs.
    Kuntsche J; Westesen K; Drechsler M; Koch MH; Bunjes H
    Pharm Res; 2004 Oct; 21(10):1834-43. PubMed ID: 15553230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(vinyl alcohol) as emulsifier stabilizes solid triglyceride drug carrier nanoparticles in the alpha-modification.
    Rosenblatt KM; Bunjes H
    Mol Pharm; 2009; 6(1):105-20. PubMed ID: 19049318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The physical state of lipid nanoparticles influences their effect on in vitro cell viability.
    Petersen S; Steiniger F; Fischer D; Fahr A; Bunjes H
    Eur J Pharm Biopharm; 2011 Sep; 79(1):150-61. PubMed ID: 21458564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization, stabilization, and characterization of amphotericin B loaded nanostructured lipid carriers for ocular drug delivery.
    Lakhani P; Patil A; Wu KW; Sweeney C; Tripathi S; Avula B; Taskar P; Khan S; Majumdar S
    Int J Pharm; 2019 Dec; 572():118771. PubMed ID: 31669555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure.
    Kovacevic A; Savic S; Vuleta G; Müller RH; Keck CM
    Int J Pharm; 2011 Mar; 406(1-2):163-72. PubMed ID: 21219990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicochemical characterization of curcuminoid-loaded solid lipid nanoparticles.
    Noack A; Hause G; Mäder K
    Int J Pharm; 2012 Feb; 423(2):440-51. PubMed ID: 22197758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control over Particle Size Distribution by Autoclaving Poloxamer-Stabilized Trimyristin Nanodispersions.
    Göke K; Roese E; Arnold A; Kuntsche J; Bunjes H
    Mol Pharm; 2016 Sep; 13(9):3187-95. PubMed ID: 27463039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parenteral formulation of an antileishmanial drug candidate--tackling poor solubility, chemical instability, and polymorphism.
    Kupetz E; Preu L; Kunick C; Bunjes H
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):511-20. PubMed ID: 23454203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and formulation optimization of solid lipid nanoparticles in vitamin K1 delivery.
    Liu CH; Wu CT; Fang JY
    Drug Dev Ind Pharm; 2010 Jul; 36(7):751-61. PubMed ID: 20136495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization.
    Attama AA; Schicke BC; Paepenmüller T; Müller-Goymann CC
    Eur J Pharm Biopharm; 2007 Aug; 67(1):48-57. PubMed ID: 17276663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media.
    Tho I; Liepold B; Rosenberg J; Maegerlein M; Brandl M; Fricker G
    Eur J Pharm Sci; 2010 Apr; 40(1):25-32. PubMed ID: 20172027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular interaction and localization of tocotrienol-rich fraction (TRF) within the matrices of lipid nanoparticles: evidence studies by Differential Scanning Calorimetry (DSC) and Proton Nuclear Magnetic Resonance spectroscopy ((1)H NMR).
    Ali H; El-Sayed K; Sylvester PW; Nazzal S
    Colloids Surf B Biointerfaces; 2010 Jun; 77(2):286-97. PubMed ID: 20189780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of lipid excipients in solid lipid nanoparticles.
    Radomska-Soukharev A
    Adv Drug Deliv Rev; 2007 Jul; 59(6):411-8. PubMed ID: 17553589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the drug loading capacity of different lipid nanoparticle dispersions by passive drug loading.
    Rosenblatt KM; Bunjes H
    Eur J Pharm Biopharm; 2017 Aug; 117():49-59. PubMed ID: 28315731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.